IGMS [NASD]
IGM Biosciences, Inc.
Index- P/E- EPS (ttm)-5.51 Insider Own1.10% Shs Outstand33.92M Perf Week-5.27%
Market Cap636.61M Forward P/E- EPS next Y-5.73 Insider Trans19.81% Shs Float16.19M Perf Month-6.01%
Income-185.40M PEG- EPS next Q-1.61 Inst Own67.80% Short Float21.66% Perf Quarter-2.86%
Sales- P/S- EPS this Y-86.50% Inst Trans2.23% Short Ratio2.86 Perf Half Y-70.80%
Book/sh6.03 P/B2.59 EPS next Y-2.10% ROA-59.90% Target Price51.22 Perf Year-78.65%
Cash/sh4.60 P/C3.40 EPS next 5Y- ROE-70.10% 52W Range12.74 - 99.44 Perf YTD-46.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.28% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low22.66% ATR1.84
Employees216 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)44.41 Volatility11.56% 11.87%
OptionableYes Debt/Eq0.00 EPS Q/Q-61.10% Profit Margin- Rel Volume0.32 Prev Close17.37
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume1.23M Price15.63
Recom1.70 SMA20-7.29% SMA50-15.36% SMA200-59.52% Volume392,794 Change-10.02%
Dec-13-21Downgrade RBC Capital Mkts Outperform → Sector Perform $51
Nov-05-21Upgrade Wedbush Neutral → Outperform
Aug-26-21Initiated Morgan Stanley Overweight $100
Jan-29-21Initiated RBC Capital Mkts Outperform $121
Jan-19-21Reiterated H.C. Wainwright Buy $88 → $114
Dec-22-20Downgrade Wedbush Outperform → Neutral
Jul-17-20Initiated Robert W. Baird Outperform $90
Jul-01-20Initiated H.C. Wainwright Buy $88
May-28-20Initiated SunTrust Buy $86
Apr-22-20Initiated Wedbush Outperform $73
Oct-14-19Initiated Stifel Buy $32
Oct-14-19Initiated Piper Jaffray Overweight $26
Oct-14-19Initiated Jefferies Buy $25
Oct-14-19Initiated Guggenheim Buy $30
May-20-22 12:07PM  
May-10-22 07:00AM  
May-09-22 04:16PM  
May-06-22 07:00AM  
Apr-09-22 09:35AM  
Apr-06-22 04:39PM  
Apr-05-22 04:56PM  
Mar-30-22 03:06PM  
02:14PM  
01:29PM  
11:57AM  
12:56AM  
Mar-29-22 11:41AM  
09:00AM  
08:54AM  
07:59AM  
07:41AM  
06:01AM  
02:00AM  
Feb-09-22 03:34PM  
07:00AM  
Feb-03-22 04:05PM  
Jan-10-22 10:00AM  
Jan-05-22 07:00AM  
Dec-13-21 09:43AM  
07:08AM  
Dec-11-21 01:31PM  
Dec-09-21 07:36AM  
Dec-08-21 07:00AM  
Dec-06-21 04:05PM  
Nov-10-21 04:05PM  
11:15AM  
Nov-08-21 07:00AM  
Nov-04-21 11:25AM  
09:21AM  
Oct-11-21 04:05PM  
Oct-06-21 11:44AM  
Sep-23-21 04:05PM  
Sep-10-21 09:01AM  
Sep-07-21 07:00AM  
Aug-09-21 04:06PM  
Jul-29-21 05:31PM  
Jul-26-21 08:17PM  
Jun-12-21 05:05AM  
Jun-03-21 07:01AM  
May-26-21 07:00AM  
May-12-21 07:00AM  
May-03-21 08:02AM  
Apr-27-21 07:00AM  
Apr-12-21 07:00AM  
Mar-30-21 04:17PM  
02:30PM  
Mar-24-21 07:00AM  
Mar-15-21 07:00AM  
Mar-14-21 05:52AM  
Mar-08-21 09:51AM  
Feb-05-21 07:00AM  
Jan-12-21 08:15AM  
Jan-11-21 06:00PM  
Jan-07-21 07:00AM  
Dec-23-20 10:32AM  
Dec-21-20 10:45AM  
Dec-17-20 01:43PM  
Dec-14-20 01:52AM  
Dec-11-20 04:05PM  
Dec-08-20 10:30PM  
Dec-07-20 05:07PM  
Dec-05-20 01:30PM  
Nov-30-20 07:00AM  
Nov-23-20 07:00AM  
Nov-16-20 09:48AM  
Nov-09-20 07:00AM  
Nov-05-20 07:02AM  
Nov-04-20 09:20AM  
Sep-30-20 07:00AM  
Sep-24-20 04:01PM  
Sep-18-20 06:51PM  
Sep-16-20 09:00AM  
Sep-14-20 12:04PM  
Sep-02-20 07:00AM  
Aug-06-20 04:08PM  
Aug-04-20 07:00AM  
Jun-28-20 05:58PM  
Jun-16-20 06:27AM  
May-28-20 07:00AM  
May-12-20 07:00AM  
May-07-20 04:03PM  
12:25PM  
Apr-29-20 04:05PM  
Apr-03-20 07:00AM  
Mar-26-20 04:05PM  
02:30PM  
Mar-19-20 07:00AM  
Mar-04-20 07:00AM  
Feb-06-20 07:00AM  
Jan-07-20 07:00AM  
Dec-22-19 01:29PM  
Nov-12-19 07:00AM  
Nov-07-19 05:04PM  
Nov-01-19 10:24AM  
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Topsoe Jakob HaldorDirectorMay 20Buy16.001,48123,69673,462May 24 05:13 PM
Keyt BruceChief Scientific OfficerApr 06Option Exercise0.932,5002,32542,515Apr 08 07:24 PM
Keyt BruceChief Scientific OfficerApr 06Sale25.002,50062,50040,015Apr 08 07:24 PM
LOBERG MICHAEL DDirectorApr 01Buy23.0021,739499,99721,739Apr 04 08:11 PM
BEHRENS M KATHLEENDirectorApr 01Buy23.0060,8691,399,987158,200Apr 04 08:10 PM
Keyt BruceChief Scientific OfficerMar 30Option Exercise0.937,5006,97547,515Apr 01 08:16 PM
Keyt BruceChief Scientific OfficerMar 30Sale28.507,500213,72540,015Apr 01 08:16 PM
Keyt BruceChief Scientific OfficerNov 02Sale51.371,32668,1173,057Nov 03 07:55 PM
Keyt BruceChief Scientific OfficerNov 01Option Exercise0.932,5002,3255,557Nov 03 07:55 PM
Keyt BruceChief Scientific OfficerOct 05Sale64.101,24279,6173,057Oct 05 09:28 PM
Keyt BruceChief Scientific OfficerOct 01Option Exercise0.932,5002,3255,557Oct 05 09:28 PM
Keyt BruceChief Scientific OfficerSep 03Sale70.691,24487,9323,057Sep 03 08:23 PM
Keyt BruceChief Scientific OfficerSep 01Option Exercise0.932,5002,3255,557Sep 03 08:23 PM
Hambleton JulieDirectorAug 09Sale80.001,00080,0002,000Aug 11 09:37 PM
Keyt BruceChief Scientific OfficerAug 04Sale67.001,24283,2143,057Aug 04 08:42 PM
Keyt BruceChief Scientific OfficerAug 02Option Exercise0.932,5002,3255,557Aug 04 08:42 PM
Keyt BruceChief Scientific OfficerJul 06Sale82.501,247102,8783,057Jul 06 07:46 PM
Chen Daniel ShinYuChief Medical OfficerJul 06Sale82.7594378,033116,518Jul 06 07:45 PM
Chen Daniel ShinYuChief Medical OfficerJul 01Option Exercise1.391,9002,641118,418Jul 06 07:45 PM
Keyt BruceChief Scientific OfficerJul 01Option Exercise0.932,5002,3255,557Jul 06 07:46 PM
Keyt BruceChief Scientific OfficerJun 02Sale79.151,24598,5423,057Jun 03 08:30 PM
Chen Daniel ShinYuChief Medical OfficerJun 02Sale79.1594174,480116,518Jun 03 08:29 PM
Chen Daniel ShinYuChief Medical OfficerJun 01Option Exercise1.391,9002,641118,418Jun 03 08:29 PM
Keyt BruceChief Scientific OfficerJun 01Option Exercise0.932,5002,3255,557Jun 03 08:30 PM
Hambleton JulieDirectorJun 01Sale80.002,000160,0003,000Jun 03 08:29 PM